Cart
sales@molnova.com
PF-00489791
CAS No. 853003-48-2
PF-00489791( —— )
Catalog No. M34372 CAS No. 853003-48-2
PF-00489791 (PF4634817) is a long-acting PDE5 inhibitor with hypotensive activity for the study of diabetic nephropathy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 93 | In Stock |
|
| 10MG | 179 | In Stock |
|
| 25MG | 302 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF-00489791
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-00489791 (PF4634817) is a long-acting PDE5 inhibitor with hypotensive activity for the study of diabetic nephropathy.
-
DescriptionPF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC50 of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number853003-48-2
-
Formula Weight476.55
-
Molecular FormulaC20H28N8O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NS(C)(=O)=O)(=O)C=1C=2C(=C(NC3=CC(C)=CC=N3)N=C(N(CC)C)N2)N(CCOCC)N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Frank S Menniti, et al. A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats. Restor Neurol Neurosci. 2012;30(4):283-9.?
molnova catalog
related products
-
Lirimilast
Lirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.
-
ATX inhibitor 5
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.
-
MBCQ
MBCQ is an inhibitor of cGMP-specific phosphodiesterase PDE5.MBCQ, a selective PDE5 inhibitor, significantly decreased the EC(50) values for GTN-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift occurring in tolerant veins.
